Aindo named as a Sample Vendor in the 2026 Gartner® Emerging Tech Impact Radar for Conversational AI

Aindo has been recognized as a “Sample Vendor” in the Synthetic Data category within the recent Gartner® report, “Emerging Tech Impact Radar: Conversational Artificial Intelligence”.

The Data Challenge in the Era of Specialized AI Agents

The market is shifting toward the creation of “expert” AI agents designed to operate in highly specialized domains. Training these sophisticated language models requires high-quality, domain-specific, and clinically meaningful data that can support reliable model development and evidence generation.

In healthcare, this challenge is even more strategic: clinical data is not only sensitive, but also fragmented, difficult to access, and often underused for research, validation, and innovation. The real opportunity is therefore not simply to protect data, but to transform it into evidence-ready assets that can support trustworthy AI development.

According to the Gartner report:

“As Al agents and conversational interfaces become more specialized, autonomous, and multimodal, they will use smaller, domain-specific models which may require synthetic data to fine-tune or train language models. There are a few reasons why this data will be synthetic. First, organizations may be unwilling to sell vendors their datasets due to privacy and security concerns. Second, synthetic data can provide more complete and unbiased datasets, which will improve model accuracy. Third, synthetic data can accelerate product go to market.”

From Theory to Practice: Advancing Cardiology with CDSS-GPT

At Aindo, we are already working in this direction through applied healthcare innovation projects. Aindo is the technology partner of Centro Cardiologico Monzino in a highly innovative clinical AI project: the creation of CDSS-GPT, an innovative clinical decision support system. This specialized Large Language Model (LLM) is designed to support clinicians in exploring diagnostic and therapeutic hypotheses related to heart failure, based on patient clinical history and domain-specific medical knowledge.

The core of this innovation shows how synthetic data can become an enabling infrastructure for clinical evidence generation and specialized AI development: CDSS-GPT was developed using clinically meaningful synthetic datasets generated from real-world cardiology data. This approach allows us to:

• Enable the use of sensitive clinical information within strong privacy and data protection safeguards.
• Provide doctors with a highly accurate cardiology LLM trained specifically on Italian clinical data.
• Transform otherwise difficult-to-access clinical data into evidence-ready assets for model development, validation, and clinical innovation.

In this perspective, synthetic data is not merely a privacy-preserving alternative to real data. It becomes a strategic layer for generating evidence: enabling healthcare organizations to train, test, and validate specialized AI systems while preserving strong data protection safeguards.

The Strategic Advantage of Acting Now

Using synthetic data drastically reduces the costs and time required to acquire real data, accelerating the go-to-market for AI solutions.

At Aindo, we are committed to empowering healthcare organizations to unlock the full potential of their clinical data, turning sensitive health data into usable, reliable, and privacy-preserving evidence for medical research, clinical AI, and healthcare innovation.

 

---

 

Source: Gartner, Emerging Tech Impact Radar: Conversational Artificial Intelligence, By Danielle Casey, Jim Hare, Annette Zimmermann, et al., 13 April 2026.
Gartner is a trademark of Gartner, Inc. and/or its affiliates. Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.